YS Biopharma Co., Ltd.
YS · NASDAQ
3/31/2025 | 9/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | – | – | $136 | $169 |
| % Growth | – | – | -19.7% | – |
| Cost of Goods Sold | – | – | $101 | $35 |
| Gross Profit | – | – | $34 | $134 |
| % Margin | – | – | 25.4% | 79.3% |
| R&D Expenses | – | – | $59 | $68 |
| G&A Expenses | – | – | $9 | $78 |
| SG&A Expenses | – | – | $63 | $150 |
| Sales & Mktg Exp. | – | – | $72 | $71 |
| Other Operating Expenses | – | – | $94 | $0 |
| Operating Expenses | – | – | $216 | $218 |
| Operating Income | – | – | -$181 | -$84 |
| % Margin | – | – | -133.7% | -49.9% |
| Other Income/Exp. Net | – | – | -$14 | -$3 |
| Pre-Tax Income | – | – | -$195 | -$88 |
| Tax Expense | – | – | -$14 | -$7 |
| Net Income | – | – | -$181 | -$80 |
| % Margin | – | – | -133.9% | -47.5% |
| EPS | – | – | -1.81 | -0.85 |
| % Growth | – | – | -112.9% | – |
| EPS Diluted | – | – | -1.81 | -0.85 |
| Weighted Avg Shares Out | – | – | 100 | 93 |
| Weighted Avg Shares Out Dil | – | – | 100 | 93 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | – | $0 | $0 |
| Interest Expense | – | – | $24 | $8 |
| Depreciation & Amortization | – | – | $11 | $9 |
| EBITDA | – | – | -$83 | -$72 |
| % Margin | – | – | -61% | -42.9% |